Td Asset Management Inc Allakos Inc. Transaction History

Td Asset Management Inc

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	BUY	$1.72 - $3.18 $87,376 - $161,544	50,800 Added 31.13%	214,004 $584,000
Q3 2023 Oct 27, 2023	BUY	$2.13 - $5.55 $92,237 - $240,337	43,304 Added 36.12%	163,204 $370,000
Q2 2023 Aug 09, 2023	BUY	$3.6 - $5.25 $136,800 - $199,500	38,000 Added 46.4%	119,900 $522,000
Q1 2023 May 10, 2023	BUY	$4.3 - $8.27 $48,590 - $93,451	11,300 Added 16.01%	81,900 $364,000
Q4 2022 Feb 06, 2023	BUY	$5.66 - $8.42 $130,746 - $194,502	23,100 Added 48.63%	70,600 $594,000
Q3 2022 Nov 07, 2022	BUY	$3.02 - $6.12 $13,590 - $27,540	4,500 Added 10.47%	47,500 $266,000
Q1 2022 May 10, 2022	BUY	$5.08 - $9.81 $137,668 - $265,851	27,100 Added 170.44%	43,000 $245,000
Q4 2021 Feb 10, 2022	BUY	$8.55 - $111.89 $135,945 - $1.78 Million	15,900 New	15,900 $156,000
Q2 2020 Aug 13, 2020	SELL	$44.04 - $80.69 $285,555 - $523,193	-6,484 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$44.49 - $93.39 $40,041 - $84,051	-900 Reduced 12.19%	6,484 $288,000
Q4 2019 Feb 11, 2020	SELL	$66.49 - $137.73 $465,429 - $964,109	-7,000 Reduced 48.67%	7,384 $704,000
Q3 2019 Nov 07, 2019	SELL	$31.0 - $89.73 $102,393 - $296,378	-3,303 Reduced 18.67%	14,384 $1.13 Million
Q2 2019 Aug 01, 2019	SELL	$36.0 - $44.73 $32,400 - $40,257	-900 Reduced 4.84%	17,687 $766,000
Q1 2019 May 08, 2019	BUY	$33.79 - $51.99 $74,338 - $114,378	2,200 Added 13.43%	18,587 $753,000
Q4 2018 Feb 01, 2019	BUY	$31.59 - $62.65 $15,795 - $31,325	500 Added 3.15%	16,387 $857,000
Q3 2018 Nov 01, 2018	BUY	$31.25 - $47.64 $496,468 - $756,856	15,887 New	15,887 $715,000

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $89.8M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Td Asset Management Inc with notifications on news.